Buskila Dan
Division of Internal Medicine, Department of Medicine H, Soroka Medical Center, Ben Gurion University, Beer Sheva, P.O.B 151, 84101 Israel.
Rheum Dis Clin North Am. 2009 Feb;35(1):111-23. doi: 10.1016/j.rdc.2009.03.005.
Hepatitis C virus (HCV) is an important causative agent of liver diseases. However, HCV infection is also associated with numerous hematologic, renal, dermatologic, rheumatic, and autoimmune disorders. These include arthralgia, arthritis, vasculitis, sicca syndrome, myalgia, and fibromyalgia. The purpose of this article is to review the prevalence and spectrum of rheumatic disorders and autoimmune phenomena in HCV-infected patients. It evaluates and current treatment options including nonsteroidal anti-inflammatory drugs, low-dose corticosteroids, hydroxychloroquine, methotrexate, penicillamine, combined antiviral therapy, cyclosporin A, anti-TNF-a agents, and rituximab. It concludes that larger, controlled studies are needed to establish further the treatment indications, efficacy, and safety of these agents.
丙型肝炎病毒(HCV)是肝脏疾病的重要致病因素。然而,HCV感染还与众多血液学、肾脏、皮肤、风湿性和自身免疫性疾病相关。这些疾病包括关节痛、关节炎、血管炎、干燥综合征、肌痛和纤维肌痛。本文的目的是综述HCV感染患者中风湿性疾病和自身免疫现象的患病率及范围。它评估了当前的治疗选择,包括非甾体抗炎药、低剂量皮质类固醇、羟氯喹、甲氨蝶呤、青霉胺、联合抗病毒疗法、环孢素A、抗TNF-α药物和利妥昔单抗。结论是需要进行更大规模的对照研究,以进一步确定这些药物的治疗指征、疗效和安全性。